Amgen, headquartered in Thousand Oaks, California, is one of the world’s largest independent biotechnology companies. Established in 1980, Amgen is focused on developing innovative medicines to treat serious illnesses such as cancer, cardiovascular diseases, and autoimmune disorders. Known for its commitment to research and development, Amgen leverages cutting-edge science and technology to deliver life-changing therapies to patients worldwide.
Amgen’s core strength lies in its biopharmaceutical research, which has led to the development of groundbreaking treatments like Neulasta, Enbrel, and Prolia. With a global presence, Amgen operates in over 100 countries and continues to expand its portfolio through strategic acquisitions and collaborations in the biotech industry.
CEO and Founder of Amgen
Amgen was founded in 1980 by a group of visionary scientists and business leaders under the original name "Applied Molecular Genetics." The company's mission was to harness the power of cellular biology to improve human health. Over the years, Amgen’s leadership has played a critical role in its success, driving the company’s focus on innovation and patient-centric therapies. The current CEO of Amgen, Robert A. Bradway, has been with the company since 2006 and became the CEO in 2012. Under his leadership, Amgen has expanded its research pipeline, pursued strategic acquisitions, and launched cutting-edge therapies that have transformed patient care.
List of Top Companies Under Amgen
Amgen has made strategic acquisitions over the years, helping to strengthen its portfolio in the biotechnology and biopharmaceutical sectors. Below is a list of top companies that have become a part of Amgen’s ecosystem, along with their valuations:
| Company Name | Year Acquired/Founded | Valuation | Industry |
|---|---|---|---|
| Onyx Pharmaceuticals | 2013 (Acquired) | $10.4 Billion | Cancer Treatment and Research |
| DeCODE Genetics | 2012 (Acquired) | $415 Million | Genomics and DNA Sequencing |
| Five Prime Therapeutics | 2021 (Acquired) | $1.9 Billion | Immuno-Oncology |
| ChemoCentryx | 2022 (Acquired) | $3.7 Billion | Inflammatory and Autoimmune Diseases |
| Kite Pharma | 2017 (Partnership) | Estimated $11.9 Billion | CAR-T Cell Therapy |
| Teneobio | 2021 (Acquired) | $900 Million | Cancer Therapy |
| Celgene (Otezla Rights) | 2019 (Acquired) | $13.4 Billion | Autoimmune Disease Treatment |
| Micromet | 2012 (Acquired) | $1.16 Billion | Antibody-based Therapeutics |
FAQs About Amgen
Q1: When was Amgen founded, and by whom?
A: Amgen was founded in 1980 by a group of scientists and business leaders. It was initially known as "Applied Molecular Genetics."
Q2: Who is the current CEO of Amgen?
A: The current CEO of Amgen is Robert A. Bradway, who took on the role in 2012.
Q3: What are some of the top drugs developed by Amgen?
A: Some of the top drugs developed by Amgen include Neulasta (for cancer patients), Enbrel (for autoimmune diseases), and Prolia (for bone diseases).
Q4: What are Amgen's strategic acquisitions?
A: Some of Amgen’s key acquisitions include Onyx Pharmaceuticals, DeCODE Genetics, Five Prime Therapeutics, and ChemoCentryx, which have expanded its capabilities in cancer treatment, genomics, and autoimmune diseases.
Q5: What is Amgen’s market capitalization?
A: As of 2024, Amgen’s market capitalization is estimated to be over $150 billion, making it one of the largest biotech companies in the world.
Q6: How is Amgen involved in cancer research?
A: Amgen is heavily involved in cancer research through its subsidiaries and partnerships, such as Onyx Pharmaceuticals and Kite Pharma, focusing on immuno-oncology and innovative cancer therapies like CAR-T cell therapy.
